Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children With Hypochondroplasia

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Oct 2025 According to a BioMarin Pharmaceutical media release, VOXZOGO pivotal data for hypochondroplasia is expected in 1H 2026, potential launch expected in 2027.
12 May 2025 According to a BioMarin Pharmaceutical media release, BioMarin completed enrollment in its pivotal Phase 3 study with VOXZOGO in hypochondroplasia in April, and the company is on track to share topline data in 2026, with potential launch in 2027.
12 May 2025 According to a BioMarin Pharmaceutical media release, status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com